Nature CommunicationsMolecular BiologyPeer-reviewed journal article
Structure-function Analyses Reveal Key Molecular Determinants of HIV-1 CRF01_AE Resistance to the Entry Inhibitor Temsavir
Jérémie PrévostiD, Yaozong CheniD, Fei Zhou, William David TolbertiD, Romain GasseriD, Halima Medjahed, Manon NayraciD, Dung Ngoc Pham NguyeniD, Suneetha Gottumukkala, Ann Jones HesselliD, Venigalla Basaveswara RaoiD, Edwin V. PozharskiiD, Rick K HuangiD, Doreen MatthiesiD, Andrés FinziiD, Marzena PazgieriD
- Citations
- 13
- FWCI
- 1.70
- Field percentile
- top 15%
Abstract
The HIV-1 entry inhibitor temsavir prevents CD4 from interacting with the envelope glycoprotein (Env) and blocks its conformational changes. To do this temsavir relies on the presence of a residue with small side chain at position 375 in Env and is unable to neutralize viral strains like CRF01_AE carrying His375. Here we investigate the mechanism of temsavir-resistance and show that residue 375 is not the sole determinant of resistance. At least six additional residues within the gp120 inner domain layers, including five distant from the drug-binding pocket, contribute to resistance. A detailed structure-function analysis using engineered viruses and soluble trimer variants reveal that the molecular basis of resistance is mediated by crosstalk between His375 and the inner domain layers. Furthermore, our data confirm that temsavir can adjust its binding mode to accommodate changes in Env conformation, a property that likely contributes to its broad-antiviral activity.
- organism: human
- assay: proteomics
- research focus: protein structure prediction
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Massively parallel profiling of HIV-1 resistance to the fusion inhibitor enfuvirtide
A. S. Dingens, D. Arenz, … J. D. Bloom·bioRxiv·Nov 19, 2018
- Comprehensive Mapping of the Virus and Host Factors that Guide the Paths of HIV-1 Escape from a Therapeutic
Aaron Nicholas Gillman, Cassian M Birler, … Hillel Haim·Cell ReportsPeer-reviewed·Jun 19, 2026
- Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations
Y. Hikichi, R. Van Duyne, … E. O. Freed·bioRxiv·Aug 6, 2020
- Mechanisms of HIV-1 Integrase Resistance to Dolutegravir and Potent Inhibition of Drug Resistant Variants
M. Li, D. Passos, … D. Lyumkis·bioRxiv·Dec 4, 2022
- Characterization of resistance to a potent D-peptide HIV entry inhibitor
A. R. Smith, M. T. Weinstock, … M. S. Kay·bioRxiv·Aug 28, 2019
- Characterization of human immunodeficiency virus (HIV-1) envelope glycoprotein variants selected for resistance to a CD4-mimetic compound
S. Anang, J. Richard, … J. G. Sodroski·bioRxiv·Apr 21, 2022